Neovacs acquires Interferon Alpha manufacturing technology from AMEGABIOTECH
Neovacs, a manufacturer of active immunotherapies for the treatment of autoimmune diseases, announced an agreement with the Argentinean company AMEGABIOTECH to acquire its interferon Alpha (IFNα) manufacturing license. IFNα is a key component of Neovacs' lead therapeutic candidate, IFNα Kinoid, which is composed of inactivated IFNα coupled with a carrier protein, keyhole limpet hemocyanin.
Miguel Sieler, CEO of Neovacs, commented: "With this agreement, the company has reinforced its ability to maintain control of its technology, quality control, manufacturing and costs, which is key to our overall growth strategy as we continue advancing the clinical development of our lead candidate IFNα Kinoid. With greater control over our Kinoid technology, we can drive optimization of manufacturing costs and more effectively support the potential commercialization of IFNα Kinoid for the treatment of lupus, a complex autoimmune disease where medical needs are urgent and unmet today."
AMEGABIOTECH is a leading global producer of IFNα protein and a long term supplier of Neovacs, particularly for its on-going Phase IIb study of IFNα Kinoid in Lupus. Their product is recognized by the international biotechnology and pharmaceutical industry for the quality of its technological manufacturing, which also meets all relevant international standards for GMP (Good manufacturing Practice).
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Roche goes on shopping spree - Billion euro purchase for stomach medicine
Genzyme Concludes Treat-to-Goal Study
Method developed by VTT targets diagnosis of early Alzheimer’s disease - Half of patients could be diagnosed a year earlier than current clinical practice
Ablynx announces an extension of its global strategic nanobody alliance with Boehringer Ingelheim

Embryonic development and cancer cell growth - Embryonic factors for reprograming cancer cells
Genzyme’s Mozobil Shows Promise in Chemosensitization
Cornell geneticists improve methods for identifying what controls complex traits

BioImage A/S - Søborg, Denmark

Breaking the coupling process - Real-time observation of signal transmission in proteins provides new insights for drug research

Cooperation of Ghost-Driving Genes - A groundbreaking study makes a decisive contribution to understanding how genes are regulated
Organizational changes at Bayer HealthCare - Streamlining administration, strengthening research and development
